Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Herbalife Nutrition Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 7.7× Herbalife Nutrition Ltd's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| BIO | HLF | |
|---|---|---|
Market Cap | $9.43B | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $356.25 | $19.96 |
52-Week Low | $241.71 | $7.75 |
Enterprise Value | $9.18B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.
The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
